Clinical Trial Update: A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for immunotherapy strategies in metastatic hormone-sensitive prostate cancer (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Phase 2, Phase 3 | Status: UNKNOWN